Abstract

>Thromboembolic stroke in paroxysmal atrial fibrillation (PAF) is associated with high disability and mortality, therefore its prediction is extremely important for clinical practice. The coagulation and fibrinolytic systems are the key factors, responsible for thrombus formation in atrial fibrillation. In this sense, it is reasonable to search for thromboembolic stroke predictors among coagulation and fibrinolytic indicators in PAF patients. This determined the aim of our study, namely to study the predictive value for thromboembolic stroke of twenty coagulation and fibrinolytic indicators in PAF patients. In this article, overall survival until stroke onset was modeled using the Kaplan-Meier curve. Multivariate Cox regression analysis was used to investigate the relationship between survival time and twenty coagulation and fibrinolytic parameters measured in 51 patients. Significant predictive value () was found for plasma TF levels (HR 1.022 [95% CI, (1.004-1.040)], FVIII levels (HR 1.084 [95% CI, (1.005-1.170)]) and vitronectin. (HR 0.946 [95% CI, (0.895-0.999)]). From the tested clinical parameters, only age and CHA2DS2-VASC score showed a predictive value for ischemic stroke occurrence (HR 1.237 [95% CI, (1.036-1.478]); HR 1.324 [95% CI, (1.054-1.662)] respectively).

Citation details of the article

Journal: International Journal of Applied Mathematics
Journal ISSN (Print): ISSN 1311-1728
Journal ISSN (Electronic): ISSN 1314-8060
Volume: 35
Issue: 6
Year: 2022

DOI: 10.12732/ijam.v35i6.6

Download Section

Download the full text of article from here.

You will need Adobe Acrobat reader. For more information and free download of the reader, please follow this link.

References

1. [1] E.J. Benjamin, P. Muntner, A. Alonso, M.S. Bittencourt, C.W. Callaway, A.P. Carson, A.M. Chamberlain, A.R. Chang, S. Cheng, S.R. Das, F.N. Delling, L. Djousse et al., Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation, 139, No 10 (2019), e56.
2. [2] J. Primo, H. Gongalves, A. Macedo, P. Russo, T. Monteiro, J. Guimarces and O. Costa, Prevalence of paroxysmal atrial fibrillation in a population assessed by continuous 24-hour monitoring, Rev. Port. Cardiol., 36 (2017), 535-546.
3. [3] Y. Chen, Y. Zhao, G. Dang, F. Ouyang, X. Chen, and J. Zeng, Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Medicine (Baltimore), 94 (2015), e2364.
4. [4] L.M. Christensen, D.W. Krieger, S. Højberg, O.D. Pedersen, F.M. Karlsen, M.D. Jacobsen, R. Worck, H. Nielsen, K. Aegidius, L.L. Jeppesen, S. Rosenbaum, J. Marstrand and H. Christensen, Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study, Eur. J. Neurol., 21 (2014), 884-889.
5. [5] A. Arauz, C. Arteaga, C. Zapata-Gsmez, C. Ramos-Ventura, B. Mindez, R. Otiniano-Sifuentes, S. Haseeb, R. Gonzalez-Oscoy, and A. Baranchuk, Embolic stroke of undetermined source: Beyond atrial fibrillation, Neurologia (Engl. Ed.), (2019), S0213-4853(19)30056-8.
6. [6] R. Rastegar, D.J. Harnick, P. Weidemann, V. Fuster, B. Coller, J.J. Badimon, J. Chesebro and M.E. Goldman, Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells, J. Amer. Coll. Cardiol., 41 (2003), 603-610.
7. [7] A. Boldt, U. Wetzel, J. Lauschke, J. Weigl, J. Gummert, G. Hindricks, H. Kottkamp and S. Dhein, Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease, Heart, 90 (2004), 400-405.
8. [8] W.E. Wysokinski, W.G. Owen, D.N. Fass, D.D. Patrzalek, L. Murphy and R.D. McBane, Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi, J. Thromb. Haemost., 2 (2004), 1637-1644.
9. [9] M.N. Negreva, K.S. Prodanova and K.D. Vitlianova, Paroxysmal atrial fibrillation is associated with early coagulation activity regardless of risk factors for embolism, Minerva. Cardiol. Angiol., 69 (2021), 269-276.
10. [10] M. Negreva, A. Zarkova, K. Prodanova and P. Petrov, Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation, Cardiol. Res., 11, (2020), 22-32.
11. [11] M. Negreva, K. Prodanova and A. Zarkova, Paroxysmal Atrial Fibrillation: An Independent Risk Factor for Prothrombotic Conditions, J. Atr. Fibrillation., 13 (2020), 2297-232.
12. [12] M.N. Negreva, K. Prodanova, K. Vitlianova, C. Madjova, Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability, Arch. Med. Sci. Atheroscler. Dis., 5 (2020), e140-e147.
13. [13] M. Negreva, S. Georgiev, K. Vitlianova, Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis, Medicine (Baltimore), 95 (2016), e5184.
14. [14] S.V. Pashkunova, The predictive role of genetic markers in the different types diabetes-related complication, International Journal of Applied Mathematics, 35, No 5 (2022), 735-744; doi:10.12732/ijam.v35i5.7.
15. [15] S.V. Pashkunova, Predicted factors for complications in patients with diabetes mellitus, International Journal of Applied Mathematics, 35, No 5 (2022), 787-794; doi:10.12732/ijam.v35i5.10.
16. [16] G. Hindricks, T. Potpara, N. Dagres, E. Arbelo, J.J. Bax, C. BlomstrvmLundqvist, G. Boriani, M. Castella, G.-A. Dan, P.E. Dilaveris, L. Fauchier, G. Filippatos, et al., 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, Eur. Heart. J., 42 (2021), 373-498.
17. [17] D.R. Cox and D. Oakes, Analysis of Survival Data, Chapman and Hall, New York, 1984.
18. [18] E.L. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, 53 (1958), 457-481.
19. [19] L. Friberg, N. Hammar and M. Rosenqvist, Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillat, Eur. Heart. J., 31 (2010), 967-975.
20. [20] P.B. Nielsen, T.B. Larsen, F. Skjøth, T.F. Overvad and G.Y.H. Lip, Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study, Sci. Rep., 6 (2016), # 27410.
21. [21] E.M. Hylek, A.S. Go, Y. Chang, N.G. Jensvold, L.E. Henault, J.V. Selby and D.E. Singer, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N. Engl. J. Med., 349 (2003), 1019- 1026.
22. [22] M. Brambilla, L. Facchinetti, P. Canzano, L. Rossetti, N. Ferri, A. Balduini, V. Abbonante, D. Boselli, L. De Marco, M.N.D. DiMinno, V. Toschi, A. Corsini, E. Tremoli and M. Camera, Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation, Thromb. Haemost., 114 (2015), 579-592.
23. [23] G. Cimmino, G. Ciccarelli and P. Golino, Role of Tissue Factor in the Coagulation Network, Semin. Thromb. Hemost., 41 (2015), 708-717.
24. [24] M. Cugno, A.V. Marzano, M. Lorini, V. Carbonelli and A. Tedeschi, Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis, PLoS One, 9 (2014), e111862.
25. [25] C.N. Ferreira, M. de O. Sousa, L.M.S. Dusse and M. das G. Carvalho, A cell-based model of coagulation and its implications, Rev. Bras. Hematol. Hemoter., 32 (2010), 416-421.
26. [26] K.T. Preissner and D. Seiffert, Role of vitronectin and its receptors in haemostasis and vascular remodeling, Thromb. Res., 89 (1998), 1-21.
27. [27] S.A. Smith, The cell-based model of coagulation, J. Vet. Emerg. Crit. Care. (San Antonio), 19 (2009), 3-10.